Evolva Provides 2017 Financial Results and Business Highlights

Cargill announces the start of commercial production of EverSweet™

REINACH, Switzerland–(BUSINESS WIRE)–Evolva (SIX:EVE) posted its
financial results today for the period from 1 January to 31 December
2017, and provided business highlights that illustrate how the Company
is executing on its strategic transformation plan which was put in place
last August.

Elements of this transformation have included accelerating growth of our
commercial products, building stronger R&D operations, successfully
streamlining our operations and fortifying our cash balance. These
elements have provided Evolva with a strong base to grow our product
revenues while strengthening our world-class research and development
capabilities to bring important products to market quickly.

Key business highlights

• EverSweetTM
  • Today, in a joint
    press release, Cargill and Evolva announced the official start
    of the commercial production of EverSweet™ to fill customer
    orders. Additionally, Cargill and Evolva reached a new agreement
    for the EverSweet™ sweetener which replaces the existing
    agreements, and adds certain additional high intensity sweeteners.
  • Under this new agreement, Evolva will receive a royalty percentage
    on the sales of EverSweet™, which will accrue to Evolva as soon as
    EverSweet™ starts generating revenues
  • Evolva will benefit from a significant reduction of operational
    and capital expenses while maintaining long term value
• Nootkatone pest control products
  • Evolva has filed for US EPA registration for the active ingredient
    nootkatone, a process that is expected to be completed by the end
    of 2018
  • In parallel, Evolva is actively engaged in discussions with
    leading pest control product companies to supply nootkatone for
    next-generation tick and mosquito products
• Resveratrol products
  • Following on the heels of the launch of our Veri-teTM
    brand, revenue growth is accelerating

Financial highlights:

• Product sales up by 82% in 2017 to reach CHF 2.0 million
• Overall revenues were CHF 6.8 million (2016: CHF 9.6m), the decline
  being related to the reduced activities on contract R&D work, which is
  in line with our announced strategy
• Cash position of CHF 97.2 million on 31 December 2017 (31 December
  2016: CHF 47.5m)

Evolva CEO Simon Waddington said, “The commercial launch of
EverSweet marks the fifth product platform that Evolva has advanced from
concept to market. We are very proud of this track-record and look
forward to advancing further products that meet important societal
needs. Evolva is a world-leader in applying cutting edge biotechnology
to allow for sustainable bioproduction of next-generation ingredients
that positively impact the health, nutrition and protection of people
and animals.”

Evolva CFO Oliver Walker commented, “Our finances are developing
in line with our financial plan. We have a solid cash position of almost
CHF 100 million, remain debt-free, and have significantly trimmed our
burn rate. By any measure, Evolva has never been in such a strong
financial position.”

Press/analyst call at 10AM CET on 20 March 2018

Simon Waddington (CEO) and Oliver Walker (CFO) will present the results
in call for media and analysts.

Dial-in numbers:
+41 (0)58 310 5000 (Europe)
+44 (0)207 107
0613 (UK)
+1 (1)631 570 5613 (USA)

The full press release text, Powerpoint presentation and annual accounts
are available on
Evolva’s website. A replay will be available as a podcast for 2
weeks after the call. The link to the podcast will be posted on Evolva’s
website.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century
mix of biotechnology and fermentation. We develop, make and sell natural
ingredients that provide significant health, wellness and nutrition
benefits to people in their daily life, but whose supply chain issues
have limited their use until now. Our flagship ingredients are stevia,
nootkatone and resveratrol. To make our world sustainable requires
nature and technology to work together as one, and our aim is to play a
(small) part in achieving this transformation. For more information see www.evolva.com.

This press release contains specific forward-looking statements, e.g.
statements including terms like believe, assume, expect or similar
expressions. Such forward-looking statements are subject to known and
unknown risks, uncertainties and other factors which may result in a
substantial divergence between the actual results, financial situation,
development or performance of the company and those explicitly or
implicitly presumed in these statements. Against the background of these
uncertainties readers should not place undue reliance on forward-looking
statements. The company assumes no responsibility to update
forward-looking statements or to adapt them to future events or
developments.

Contacts

Evolva
Oliver Walker, + 41 61 485 2034
CFO
oliverw@evolva.com
or
Paul
Verbraeken, + 41 61 485 2035
IR
paulv@evolva.com
or
Stephan
Herrera, + 1 415 794 4005
USA
stephanh@evolva.com